MX2021005113A - Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística. - Google Patents

Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística.

Info

Publication number
MX2021005113A
MX2021005113A MX2021005113A MX2021005113A MX2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A
Authority
MX
Mexico
Prior art keywords
cystic fibrosis
methods
amino acid
increasing
acid compositions
Prior art date
Application number
MX2021005113A
Other languages
English (en)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Xiaodong Xu
Shanshan Lin
Sreekala Prabhakaran
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2021005113A publication Critical patent/MX2021005113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen composiciones de aminoácidos útiles para aumentar la translocación de la proteína de conductancia transmembrana de la fibrosis quística (CFTR) desde el citoplasma a la membrana plasmática, particularmente en células epiteliales. También se proporcionan métodos para aumentar la concentración de CFTR en la membrana plasmática, aumentar el transporte de iones cloruro y aumentar el transporte de agua. Estas composiciones y métodos son útiles para tratar la fibrosis quística en sujetos que portan una o más mutaciones en la proteína CFTR. El uso de estas composiciones para el tratamiento de la fibrosis quística y en la preparación de un medicamento para el tratamiento de la fibrosis quística también se incluye en este documento.
MX2021005113A 2018-10-30 2019-10-30 Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística. MX2021005113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Publications (1)

Publication Number Publication Date
MX2021005113A true MX2021005113A (es) 2021-06-15

Family

ID=70464502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005113A MX2021005113A (es) 2018-10-30 2019-10-30 Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística.

Country Status (10)

Country Link
US (1) US20210393584A1 (es)
EP (1) EP3873453A4 (es)
JP (1) JP2022506044A (es)
KR (1) KR20210086660A (es)
CN (1) CN113164425A (es)
AU (1) AU2019370363A1 (es)
BR (1) BR112021008395A2 (es)
CA (1) CA3116015A1 (es)
MX (1) MX2021005113A (es)
WO (1) WO2020092639A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024033A2 (pt) * 2020-05-29 2022-12-20 Univ Florida Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) * 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
ITTO20010804A1 (it) * 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
JP4569106B2 (ja) * 2001-12-25 2010-10-27 味の素株式会社 臓器線維化抑制剤
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
US8389736B2 (en) * 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
ITTO20080443A1 (it) * 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
ES2656321T3 (es) * 2012-05-17 2018-02-26 I.E.R.F.C. European Institute For Cystic Fibrosis Research Terapia combinada para fibrosis quística
WO2016191263A1 (en) * 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
CA3028966A1 (en) * 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Substituted phenyl-isoxazole-carboxamide compounds and use thereof for increasing cftr activity

Also Published As

Publication number Publication date
EP3873453A1 (en) 2021-09-08
US20210393584A1 (en) 2021-12-23
WO2020092639A1 (en) 2020-05-07
EP3873453A4 (en) 2022-08-03
KR20210086660A (ko) 2021-07-08
JP2022506044A (ja) 2022-01-17
CA3116015A1 (en) 2020-05-07
CN113164425A (zh) 2021-07-23
BR112021008395A2 (pt) 2021-09-28
AU2019370363A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
MX2021005113A (es) Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística.
MX2019013752A (es) Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
ZA202004357B (en) Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
AU2017260706A1 (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
SG10201913575VA (en) Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CL2011000919A1 (es) Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
WO2014081821A3 (en) Small Molecule Bicyclic and Tricyclic CFTR Correctors
Laselva et al. Small-molecule drugs for cystic fibrosis: Where are we now?
WO2005120497A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
MX2010005919A (es) Formulaciones de proteinas y metodos para elaborarlas.
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
MX2022007943A (es) Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas.
MX2017007497A (es) Polimeros de union a protones para administracion oral.
PH12020550117A1 (en) Variant rnai
MX337114B (es) Soluciones que comprenden polietilenglicol y electrolitos.
WO2019055996A8 (en) Polymer nanodiscs for biotechnology and medical applications
EA201391006A1 (ru) Гипотоническая водная композиция с пониженным содержанием хлора и с или без фосфолипидов
MX2019012347A (es) Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
WO2013134129A3 (en) Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
WO2018237174A3 (en) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS
WO2021091938A8 (en) Cochlear outer hair cell promoters and uses thereof
MX2021011677A (es) Uso del gen kdm5a y del gen atrx.
Marra et al. Amikacin reverse iontophoresis: optimization of in vitro extraction
MX2018004365A (es) Combinaciones de potenciador-corrector utiles en el tratamiento de fibrosis quistica.